Novavax (NVAX) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Novavax (NVAX) has outperformed Taysha Gene Therapies (TSHA) over the past year, gaining 23.7% versus a loss of 12.5%. Over five years, TSHA leads with a -75.2% price change compared with -93.2% for NVAX. Novavax is the larger company by market cap ($2.09 billion vs $1.46 billion), about 1.4 times the size.
Novavax converts more of its revenue into profit, with a net margin of 39.2% versus -1115.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVAX | TSHA |
|---|---|---|
| Share price | $12.70 | $4.49 |
| Market cap | $2.09B | $1.46B |
| 1-day change | +15.34% | +1.35% |
| YTD return | +63.84% | -19.45% |
| 1-year return | +23.71% | -12.45% |
| 5-year return | -93.20% | -75.22% |
| EPS (TTM) | $-1.58 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.12B | $9.77M |
| Revenue growth (YoY) | +64.69% | +17.28% |
| Net income (latest FY) | $440.30M | $-109.00M |
| Gross margin | 93.50% | — |
| Operating margin | 40.30% | -1130.65% |
| Net margin | 39.19% | -1115.27% |
| 52-week high | $13.39 | $7.30 |
| 52-week low | $6.20 | $3.69 |
| Distance from 52-week high | -5.16% | -38.49% |
| Analyst consensus | buy | none |
| Avg. price target upside | +10.25% | +189.53% |
| Average volume | 5.21M | 3.28M |
| Shares outstanding | 164.95M | 325.83M |
| Employees | 749 | 99 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVAX has outperformed TSHA by 36.2 percentage points over the past year.
- Novavax is more profitable, keeping 39.2 cents of every revenue dollar as net income versus -1115.3 cents for Taysha Gene Therapies.
- Novavax grew revenue faster in its latest fiscal year (+64.69% vs +17.28%).
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 99 employees
NVAX vs TSHA FAQ
Which is bigger, Novavax or Taysha Gene Therapies?
Novavax (NVAX) is larger, with a market capitalization of $2.09B compared with $1.46B for Taysha Gene Therapies (TSHA).
Which stock has performed better over the past year, NVAX or TSHA?
NVAX returned +23.71% over the past 12 months, compared with -12.45% for TSHA (price return, excluding dividends). Past performance does not predict future results.
Are Novavax and Taysha Gene Therapies in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.